NextCure, Inc.
NXTC
Positions held
Your positionsNXTC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $31.03M | Enterprise value | $15.61M | Trailing P/E | — | Forward P/E | -1.15 |
| PEG | — | Price / book | 2.27 | Beta | 1.35 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.0% | ROA | -69.0% | Debt / equity | 0.38 |
| Current ratio | 3.47 | Free cash flow | -$23.10M | Analyst recommendation | none | Mean target | $20.00 |
| 52w high | $15.74 | 52w low | $1.55 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$14.9M | -$9.8M | -$9.4M | -$8.6M | -$26.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.0M | -$10.1M | -$9.8M | -$8.9M | -$27.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$55.8M | -$55.7M | -$62.7M | -$74.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$57.6M | -$57.2M | -$67.6M | -$75.9M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-06 · NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-07-15 · Top Premarket Decliners
2026-07-14 · Sector Update: Healthcare Stocks Fall Late Afternoon
2026-07-14 · Top Midday Gainers
2026-07-14 · Sector Update: Healthcare Stocks Fall Tuesday Afternoon
2026-07-14 · BC-Most Active Stocks
2026-07-14 · Sector Update: Healthcare Stocks Mixed Premarket Tuesday
2026-07-14 · Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
2026-07-14 · Top Premarket Gainers
2026-07-14 · NextCure to Merge With Avere Therapeutics in All-Stock Deal
2026-07-14 · NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
Price (daily)
Full chart · RSI · MACD · patterns